Obermatt
See Similar Stocks →

MacroGenics

NSQ:MGNX · US5560991094
BiotechnologySmall

360

24
Profit price59
Owner Earnings Yield1
Dividend Yield1
Price/Sales97
Price/Book93
Return on Capital33
Cash Return on Capital4
Return on Equity18
EBIT Margin54
Gross Profitability45
Accruals15
Owner Earnings Margin73
Sales growth51
Profit growth87
Reinvestment34
Price momentum69
Debt load7
Refinancing1
Debt Payback1
Liquidity80
Analyst ratings7
Opinion Changes50
Price Target Upside24
Market mood23
Value Creation2/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

MacroGenics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2000
Employees278
Websitemacrogenics.com
ISINUS5560991094
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
DiabetesInfectious DiseasesHematologyImmunologyOncologyBiotechnologyHealth CareManufacturing

Description

MacroGenics, Inc. (MacroGenics), a clinical-stage biopharmaceutical company, focuses on developing innovative antibody-based therapeutics for the treatment of cancer. The company generates its pipeline of product candidates from its proprietary suit…

Analysis

Middle-of-the-road

MacroGenics, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is solid; the safety picture is stretched. The company scores 2/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
27
2026

All-time high

29

Mar 2026

All-time low

27

Jun 2026

Average rank

28

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
97
—
—
—
Price/Earnings
43
—
—
—
Price/Book
93
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
92
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare MacroGenics with its peers
Sellas Life Sciences
NAQ:SLS
62
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Surrozen
NAQ:SRZN
33
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Incyte
NSQ:INCY
95
CountryUSA
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Xencor
NMQ:XNCR
13
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Arcellx
NSQ:ACLX
67
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Atea Pharmaceuticals
NSQ:AVIR
5
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →